The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...

Please provide your email address to receive an email when new articles are posted on . Among adults with type 2 diabetes, biosimilar insulin was noninferior to insulin glargine for lowering HbA1c, ...

The upward trajectory of insulin prices in the United States seems to be hitting a speed bump, as two of the biggest manufacturers are now pledging to restrain increases and offer discounts to ...

Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

INDIANAPOLIS (WISH) — Indianapolis-based Eli Lilly and Company is offering a response following a Monday protest about insulin prices by a diabetes patient advocate group. T1 International is a ...

Diabetes mellitus is a problem more and more people suffer from nowadays. There are two main types of diabetes – type 1 (when people’s bodies cannot produce enough insulin on their own) and type 2 ...

When the US Food and Drug Administration (FDA) approved Semglee, the first interchangeable biosimilar insulin, the agency pitched it as having the potential to be less costly than insulins currently ...

Eli Lilly is cutting the price of its insulin products, announcing Wednesday a plan to reduce the cost of its branded drug Humalog and set a $25-per-vial cap on a non-branded Humalog alternative. The ...

(Reuters) -Eli Lilly said on Thursday its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients ...